Paper Details

  1. Home
  2. Paper Details

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

Author: BurnettAlan K, CraddockCharles F, DufvaInge Hoegh, FreemanSylvie, HillsRobert K, HunterAnn E, KellJonathan, KjeldsenLars, MilliganDonald, RussellNigel H, WheatleyKeith, YinJohn

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

While treatments for acute myeloid leukemia (AML) have improved for younger patients, there's been little progress for older adults. This study aims to improve treatment outcomes for older AML patients by modifying the initial chemotherapy regimen. A previous study in younger patients showed better survival for most patients when adding gemtuzumab ozogamicin (GO) to chemotherapy.
Paper Details　
Original Abstract of the Article :
There has been little survival improvement in older patients with acute myeloid leukemia (AML) in the last two decades. Improving induction treatment may improve the rate and quality of remission and consequently survival. In our previous trial, in younger patients, we showed improved survival for t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2012.42.2964

データ提供：米国国立医学図書館（NLM）

Gemtuzumab Ozogamicin: A New Hope for Older Patients with AML

Acute myeloid leukemia (AML) is a complex and often challenging condition, particularly for older patients. This study investigates the potential of adding gemtuzumab ozogamicin (GO) to induction chemotherapy for older patients with AML. The researchers used a [research methodology] to assess the impact of GO on survival rates. It's like a search for a new oasis in the vast desert of AML treatment, seeking a path toward better outcomes for older patients.

Improved Survival with Gemtuzumab Ozogamicin

The study found that adding GO to induction chemotherapy improved survival rates in older patients with AML. This finding is like discovering a hidden spring in the desert, offering a source of hope and a better chance for survival.

Enhancing Treatment Options for AML

This research provides a glimmer of hope for older patients battling AML. The addition of GO to induction chemotherapy offers a promising avenue for improved survival. It's like finding a new route through the desert, leading to a more favorable destination.

Dr. Camel's Conclusion

This study is a testament to the ongoing search for better treatments for AML. The addition of GO to induction chemotherapy represents a significant step forward, particularly for older patients. It's like finding a new oasis in the vast desert of AML treatment, offering a chance for a brighter future.

Date :
  1. Date Completed 2013-01-17
  2. Date Revised 2022-02-24
Further Info :

Pubmed ID

22851554

DOI: Digital Object Identifier

10.1200/JCO.2012.42.2964

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.